Evidence map›Paper›PMID 42170739›Full record

ArticleCirculation2026

Sam68 Exacerbates Pathologic Cardiac Hypertrophy by Suppressing Cardiomyocyte Glucose Oxidation.

Junqing An, Chaoshan Han, Ying Jiang, Jiawei Shi, Huadong Li, Chenqi Wang, Jianrong Huang, Shiyue Xu, Jie Ni, Yangpo Cao and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Junqing An *Department of Pharmacology, Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China (J.A., C.H., C.W., J.H., J.N., Y.C., Y.F., G.Q.).
Chaoshan Han *Department of Pharmacology, Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China (J.A., C.H., C.W., J.H., J.N., Y.C., Y.F., G.Q.).
Ying JiangDepartments of Cardiology (Y.J.), Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Jiawei ShiCardiovascular Surgery (J.S., H.L., N.D.), Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Huadong LiCardiovascular Surgery (J.S., H.L., N.D.), Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Chenqi WangDepartment of Pharmacology, Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China (J.A., C.H., C.W., J.H., J.N., Y.C., Y.F., G.Q.).
Jianrong HuangDepartment of Pharmacology, Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China (J.A., C.H., C.W., J.H., J.N., Y.C., Y.F., G.Q.).
Shiyue XuDepartment of Hypertension and Vascular Disease, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China (S.X.).ORCID 0000-0001-6495-4602
Jie NiDepartment of Pharmacology, Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China (J.A., C.H., C.W., J.H., J.N., Y.C., Y.F., G.Q.).ORCID 0000-0002-5306-4759
Yangpo CaoDepartment of Pharmacology, Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China (J.A., C.H., C.W., J.H., J.N., Y.C., Y.F., G.Q.).ORCID 0000-0001-7386-8247
Yuliang FengDepartment of Pharmacology, Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China (J.A., C.H., C.W., J.H., J.N., Y.C., Y.F., G.Q.).ORCID 0000-0002-7997-163X
Qing LyuMedical Research Center, Chongqing General Hospital, Chongqing University, China (Q.L.).ORCID 0000-0002-1325-6828
Nianguo DongCardiovascular Surgery (J.S., H.L., N.D.), Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.ORCID 0000-0001-5437-599X
Gangjian QinDepartment of Pharmacology, Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China (J.A., C.H., C.W., J.H., J.N., Y.C., Y.F., G.Q.).ORCID 0000-0002-3135-7307

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetabolic remodeling, marked by maladaptive shifts in substrate use and energy production, is a hallmark of pathologic cardiac hypertrophy. Yet the mechanisms linking stress signaling to impaired myocardial glucose oxidation remain incompletely defined. Sam68 (Src-associated in mitosis, 68 kDa; also known as

methodsSAM68 expression was examined in failing human hearts and transcriptomic data sets. Cardiomyocyte-specific Sam68 knockout mice (Sam68cKO) and AAV9 (adeno-associated virus serotype 9)-cTnT (cardiac troponin T)-mediated cardiomyocyte Sam68 overexpression (Sam68OE) were studied in transverse aortic constriction and angiotensin II models. Mechanistic studies included RNA sequencing, targeted metabolomics, in vivo [U-

resultsSam68 was increased in failing human cardiomyocytes and in murine hypertrophic hearts. Sam68cKO markedly attenuated angiotensin II- and transverse aortic constriction-induced hypertrophy, whereas Sam68OE aggravated remodeling and dysfunction. In vivo [U-

conclusionsSam68 is a stress-activated cardiomyocyte scaffold that drives pathologic hypertrophy through a Src-STAT3-PDK4 program that inhibits PDH and suppresses glucose oxidation. Genetic or pharmacologic disruption of this axis restores PDH-dependent pyruvate oxidation and limits pressure-overload remodeling, identifying Sam68 as a druggable metabolic control node in heart failure.

Indexed as

Adaptor Proteins, Signal TransducingCardiomegalyDNA-Binding ProteinsGlucoseMyocytes, CardiacRNA-Binding ProteinsAnimalsHumansMaleMiceMice, KnockoutOxidation-ReductionAdaptor Proteins, Signal TransducingDNA-Binding ProteinsGlucoseKHDRBS1 protein, humanKhdrbs1 protein, mouseRNA-Binding Proteinscardiomegalyheart failurepyruvate dehydrogenase kinase 4ventricular remodeling

Identifiers

PMID42170739
PMCPMC13286121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.